drugset / Trial / NCT04086147
CHinese Acute Tissue-Based Imaging Selection for Lysis In Stroke -Tenecteplase
Phase 2
Completed
86 enrolled
Huashan Hospital
First People's Hospital of Shenyang · collabNingbo No. 1 Hospital · collabPu'er City People's Hospital · collabShanghai 10th People's Hospital · collabShanghai 5th People's Hospital · collabShanghai 6th People's Hospital · collabShanghai East Hospital · collabShuGuang Hospital · collabThe First Affiliated Hospital of Shanxi Medical University · collabThe Second Affiliated Hospital of Chongqing Medical University · collabThe Second People's Hospital of Huai'an · collabZhejiang Province People's Hospital · collab
RandomizedParallel-groupSingle-blindTreatment
Summary
To select the best dosage of tenecteplase for acute ischemic stroke patients (onset time 4.5-24h) of large vessel occlusion using early combined CT/MR imaging outcomes
Timeline
- Start
- 2019-12-09
- Primary completion
- 2021-12-31
- Completion
- 2021-12-31
Publications
- Liu X, Hong L, Zhao G, He Z, Wang X, Zhu J, Li S, Zhang A, Cao N, Ling Y, Chen X, Guo Y, Fang Q, Wang Z, Dong Q, Cheng X. Regional perfusion parameters as potential indicators of parenchymal hematoma risk following reperfusion therapy for acute ischemic stroke in the extended time window. Ther Adv Neurol Disord. 2025 Dec 21;18:17562864251406032. doi: 10.1177/17562864251406032. eCollection 2025.
- Hong L, Zhu J, He Z, Wang X, Li S, Liu X, Ling Y, Yang L, Fang Q, Dong Q, Cheng X; CHABLIS-T Investigators. Effect of Time Delay on Reperfusion After Tenecteplase in an Extended Time Window: Analysis From the CHABLIS-T Trials. J Am Heart Assoc. 2025 Jun 17;14(12):e040994. doi: 10.1161/JAHA.124.040994. Epub 2025 Jun 11.
- Cheng X, Hong L, Churilov L, Lin L, Ling Y, Zhang J, Yang J, Geng Y, Wu D, Liu X, Zhou X, Zhao Y, Zhai Q, Zhao L, Chen Y, Guo Y, Yu X, Gong F, Sui Y, Li G, Yang L, Gu HQ, Wang Y, Parsons M, Dong Q; CHABLIS-T collaborators. Tenecteplase thrombolysis for stroke up to 24 hours after onset with perfusion imaging selection: the umbrella phase IIa CHABLIS-T randomised clinical trial. Stroke Vasc Neurol. 2024 Nov 5;9(5):551-559. doi: 10.1136/svn-2023-002820.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tenecteplase | Protein / enzyme biologic | 0.25 mg/kg | Intravenous |
| Subject | Tenecteplase | Protein / enzyme biologic | 0.32 mg/kg | Intravenous |